… We identified all patients with metastatic EGFR exon19del or L858R-mutant lung cancers
treated with first/second-generation EGFR tyrosine kinase inhibitors (TKIs) with pretreatment …

… ~90% of EGFR activating mutations (5). The activating mutations of EGFR are the targets
of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Current treatment guidelines recommend …

… The second-generation EGFR-TKI dacomitinib has also recently been approved for … of
EGFR-TKIs in this setting, including EGFR-TKIs as monotherapy or in combination with other TKIs / …

… lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutation
with EGFR-TKIs … to first- or second-generation EGFR-TKIs in addition to the appearance of …

… Lung cancer is the leading cause of cancer-related death … drugs such as EGFR tyrosine
kinase inhibitors (TKI) and immune-… therapeutic outcome in non–small cell lung cancer (NSCLC). …

… Although sensitivity of EGFR TKIs to some uncommon mutations are known (L861Q, G719X…
of different anti-EGFR TKIs across a diversity of second-site EGFR TKI mutations and the …

… tumor changes. This comprehensive review describes the identified mechanisms connected
with intrinsic EGFR-TKI-… among clinically implemented EGFR-TKIs of different generations. …

… of EGFR TKI can prolong the median PFS in EGFR TKI-resistant NSCLC patients [33, 34]. …
And the combination of EGFR TKI and chemotherapy targeted EGFR TKI-sensitive and -…

… Activating epidermal growth factor receptor (EGFR) gene mutations are a positive
predictive factor for EGFR tyrosine kinase inhibitors (TKIs). For common EGFR mutations (Del19, …

… selection after progression on EGFR TKIs remains complex. … and history of the approval of
EGFR TKIs, their efficacy and … mechanisms of resistance to EGFR TKIs, ongoing attempts to …